Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
16.68
+0.21 (1.28%)
Oct 19, 2026, 2:57 PM EDT - Market open
Immunome Revenue
In the year 2025, Immunome had annual revenue of $6.94M, down -23.23%. That makes Immunome the 40,644th largest company in the world by revenue and 5,435th in the United States.
Revenue (ttm)
$6.94M
Revenue Growth
-23.23%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
247
Market Cap
1.89B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.94M | -2.10M | -23.23% |
| Dec 31, 2024 | 9.04M | -4.98M | -35.50% |
| Dec 31, 2023 | 14.02M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.97B |
| Lakefront Biotherapeutics NV | 1.13B |
| Novavax | 413.80M |
| Maravai LifeSciences Holdings | 208.78M |
| Mesoblast | 120.25M |
| Agios Pharmaceuticals | 98.34M |
| Zymeworks | 37.13M |
| ADARx Pharmaceuticals | 6.13M |
IMNM News
- 3 days ago - Immunome initiated with an Outperform at William Blair - TheFly
- 12 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - Immunome initiated with a Hold at Stifel - TheFly
- 19 days ago - Immunome announces IND clearance for IM-1340 in solid tumors - TheFly
- 19 days ago - Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors - Business Wire
- 4 weeks ago - Immunome initiated with a Buy at Alliance Global - TheFly
- 5 weeks ago - Immunome Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 5 weeks ago - Immunome Slides: Corporate presentation - Filings